Publication: Quartz crystal microbalance-based biosensor for the detection of α-thalassemia 1 (SEA deletion)
dc.contributor.author | Sirinart Chomean | en_US |
dc.contributor.author | Tiparat Potipitak | en_US |
dc.contributor.author | Chamras Promptmas | en_US |
dc.contributor.author | Wanida Ittarat | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.date.accessioned | 2018-09-24T08:42:59Z | |
dc.date.available | 2018-09-24T08:42:59Z | |
dc.date.issued | 2010-09-01 | en_US |
dc.description.abstract | Background: DNA piezoelectric biosensors have become a promising tool in molecular medicine since they do not require any label or staining. Here, a DNA piezoelectric biosensor based on a quartz crystal microbalance (QCM) was created to identify abnormal genes causing α-thalassemia 1 (SEA deletion). Methods: The functionalized gold electrode of the quartz crystal was coated with avidin and the biotinylated DNA probe was attached. The target gene causing α-thalassemia 1 was amplified and hybridized with the immobilized probe. DNA hybridization was indicated by changes in the quartz resonance frequencies. Diagnostic ability of the new α-thalassemia 1 biosensor was validated using both known and unknown blood samples. Specificity was tested using samples of β-thalassemia and α-thalassemia 2. Stability of the sensor was also evaluated. Results: The new biosensor could clearly identify α-thalassemia 1 (SEA deletion), both carrier and disease states, from the normal genotype. Identification accuracy was compatible to the standard gel electrophoresis. It was specific only to α-thalassemia 1 since no cross reaction was found with β-thalassemia and α-thalassemia 2. The sensor could be kept at room temperature up to 6 months with consistent identification accuracy. Conclusions: The label free QCM based biosensor was successfully developed to diagnose an abnormal human globin gene causing α-thalassemia 1 (SEA deletion). Its accuracy, specificity and sensitivity were comparable to the standard method. Its stable diagnostic potency up to 6 months implied its field application in thalassemic control program. © 2010 by Walter de Gruyter Berlin New York. | en_US |
dc.identifier.citation | Clinical Chemistry and Laboratory Medicine. Vol.48, No.9 (2010), 1247-1254 | en_US |
dc.identifier.doi | 10.1515/CCLM.2010.258 | en_US |
dc.identifier.issn | 14374331 | en_US |
dc.identifier.issn | 14346621 | en_US |
dc.identifier.other | 2-s2.0-77957292009 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/28641 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957292009&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Medicine | en_US |
dc.title | Quartz crystal microbalance-based biosensor for the detection of α-thalassemia 1 (SEA deletion) | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957292009&origin=inward | en_US |